Status:
COMPLETED
A Long-term (12 Months) Safety, Tolerability and Efficacy Study of LCZ696 in Patients With Essential Hypertension
Lead Sponsor:
Novartis Pharmaceuticals
Conditions:
Essential Hypertension
Eligibility:
All Genders
Phase:
PHASE2
Brief Summary
The purpose of this study is to assess the long-term safety, tolerability and efficacy of LCZ696.
Eligibility Criteria
Inclusion
- Patients who have successfully completed protocol No. CLCZ696A2219 and who, as judged by the study investigator, are able to continue in the current study.
- Ability to communicate and comply with all study requirements and demonstrate good medication compliance during CLCZ696A2219.
Exclusion
- Patients who did not complete CLCZ696A2219.
- Presence of significant protocol violation in CLCZ696A2219.
- Patients who are deemed to be unable to comply with the protocol by the investigator.
- Other protocol-defined inclusion/exclusion criteria may apply
Key Trial Info
Start Date :
November 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
April 1 2012
Estimated Enrollment :
341 Patients enrolled
Trial Details
Trial ID
NCT01256411
Start Date
November 1 2010
End Date
April 1 2012
Last Update
October 21 2015
Active Locations (33)
Enter a location and click search to find clinical trials sorted by distance.
1
Novartis Investigative Site
Chongqing, Chongqing Municipality, China, 400042
2
Novartis Investigative Site
Shijiazhuang, Hebei, China, 050000
3
Novartis Investigative Site
Hangzhou, Zhejiang, China, 310006
4
Novartis Investigative Site
Beijing, China, 100044